GVS (GVS) Q4 2024 earnings summary

Executive summary

• Revenue grew 1.5% year-over-year to €428.5 million, with adjusted EBITDA up 9.3% to €103.9 million and margin rising 190 basis points to 24.3%.

• Adjusted net income increased 52% to €47.7 million, with margin improving from 7.4% to 11.1%.

• Net financial position improved to €219.8 million, with leverage ratio reduced to 2.1x from 3.5x.

• Strong cash generation and a €75 million shareholder loan conversion supported deleveraging.

Financial highlights

• Organic growth was mainly driven by pricing, with a small volume contribution and a €2.7 million negative FX impact.

• Adjusted EBITDA margin expanded to 24.3%, up from 22.4% in FY 2023.

• Adjusted net financial expenses fell to €14.2 million from €16.0 million.

• Operating cash flow reached €109.0 million, supporting deleveraging.

• Net financial position improved by €108.9 million to €219.8 million.

Outlook and guidance

• 2025 guidance targets mid- to high single-digit revenue growth, with acceleration expected after Q2 as the Transfusion Medicine division ramps up.

• Adjusted EBITDA margin is expected to improve by 150–250 basis points, aiming for 27%.

• Leverage ratio forecasted to fall below 2x by year-end 2025.

• Strategic focus on M&A integration, new product launches, and organizational restructuring in Healthcare.

• New product launches in 2025 will have marginal impact, with a 2% revenue contribution expected in 2026.